FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2953906311> ?p ?o ?g. }

• W2953906311 abstract "Objective: To determine safety, tolerability and PK/PD in patients with Type 2 or 3 SMA who received risdiplam for the duration of the SUNFISH Part 1 dose-finding study, and exploratory efficacy data in patients treated for at least 1 year in Part 1. Background: SMA is caused by reduced levels of survival of motor neuron (SMN) protein from deletions and/or mutations of the SMN1 gene. While SMN1 produces full-length SMN protein, a second gene, SMN2 , produces low levels of functional SMN protein. Risdiplam (RG7916/RO7034067) is an investigational, orally administered, centrally and peripherally distributed small molecule that modulates SMN2 pre-mRNA splicing towards the production of full-length SMN2 mRNA to increase SMN protein levels. Design/Methods: SUNFISH (NCT02908685) is an ongoing multicenter, double-blind, placebo-controlled, operationally seamless study (randomized 2:1, risdiplam:placebo) in patients aged 2–25 years, with Type 2 or 3 SMA. Part 1 (n=51) assesses safety, tolerability and PK/PD of different risdiplam dose levels. Pivotal Part 2 (n=180) is assessing the safety and efficacy of the risdiplam dose level that was selected based on results from Part 1. Results: SUNFISH Part 1 included patients of broad age ranges and clinical characteristics (functional level, scoliosis and contractures). To date, a sustained, >2-fold increase in median SMN protein versus baseline was seen after 1 year of risdiplam. Adverse events have been mostly mild, resolved despite ongoing treatment and reflect the underlying disease. No drug-related safety findings have led to withdrawal. Safety, tolerability and PK/PD will be presented from all patients in Part 1. Exploratory efficacy will be presented in patients treated for ≥1 year. Conclusions: To date, risdiplam has been shown to be well tolerated and leads to sustained increases in SMN protein. Despite not being designed and powered to detect efficacy, patients on risdiplam experienced improvement over 12 months on the Motor Function Measure versus natural history. Disclosure: Dr. Mercuri has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with SMA studies for AveXis, Biogen, Ionis Pharmaceuticals, Inc., Novartis, and Roche. Dr. Mercuri has received research support from Ionis Pharmaceuticals, Inc./Biogen and Roche clinical trials, Famiglie SMA Italy, Italian Telethon, and SMA Europe. Dr. Baranello has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with PTC Therapeutics and Sarepta Therapeutics. Dr. Kirschner has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with AveXis, Biogen, Ionis Pharmaceuticals, Inc., Novartis, and Roche. Dr. Kirschner has received research support from Biogen, Roche, Santhera, and PTC Therapeutics. Dr. Servais has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Avexis, Sarepta, Dynacure, Pfizer, Servier, Roche and Cytokinetics. Dr. Servais has received research support from Roche, Valerion, Dynacure, Biogen and Avexis. Dr. Goemans has nothing to disclose. Dr. Pera has nothing to disclose. Dr. Buchbjerg has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche. Dr. Yeung has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Roche Products Ltd. Dr. Kletzl has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche. Dr. Kletzl holds stock and/or stock options in F. Hoffmann-La Roche which sponsored research in which Dr. Kletzl was involved as an investigator. Dr. Kletzl holds stock and/or stock options in F. Hoffmann-La Roche. Dr. Kletzl has received research support from F. Hoffmann-La Roche. Dr. Gerber has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche. Dr. Gerber has received royalty, license fees, or contractual rights payments from Hoffmann-La Roche. Dr. Gerber holds stock and/or stock options in F. Hoffmann-La Roche which sponsored research in which Dr. Gerber was involved as an investigator. Dr. Czech has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann–LaRoche. Dr. Cleary has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F.Hoffmann-La Roche. Dr. Gorni has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with F. Hoffmann-La Roche. Dr. Khwaja has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Hoffmann-La Roche. Dr. Khwaja holds stock and/or stock options in Hoffmann-La Roche which sponsored research in which Dr. Khwaja was involved as an investigator. Dr. Khwaja holds stock and/or stock options in Hoffmann-La Roche. Dr. Khwaja has received research support from Hoffmann-La Roche." @default.
• W2953906311 created "2019-07-12" @default.
• W2953906311 creator A5002197436 @default.
• W2953906311 creator A5002367971 @default.
• W2953906311 creator A5012816116 @default.
• W2953906311 creator A5012996195 @default.
• W2953906311 creator A5014752554 @default.
• W2953906311 creator A5030692760 @default.
• W2953906311 creator A5038576080 @default.
• W2953906311 creator A5043897574 @default.
• W2953906311 creator A5058605651 @default.
• W2953906311 creator A5061093150 @default.
• W2953906311 creator A5065043368 @default.
• W2953906311 creator A5070232710 @default.
• W2953906311 creator A5072476751 @default.
• W2953906311 creator A5076660780 @default.
• W2953906311 date "2019-04-09" @default.
• W2953906311 modified "2023-09-23" @default.
• W2953906311 title "Update from SUNFISH Part 1: Safety, Tolerability and PK/PD from the Dose-Finding Study, Including Exploratory Efficacy Data in Patients with Type 2 or 3 Spinal Muscular Atrophy (SMA) Treated with Risdiplam (RG7916) (S25.007)" @default.
• W2953906311 hasPublicationYear "2019" @default.
• W2953906311 type Work @default.
• W2953906311 sameAs 2953906311 @default.
• W2953906311 citedByCount "0" @default.
• W2953906311 crossrefType "journal-article" @default.
• W2953906311 hasAuthorship W2953906311A5002197436 @default.
• W2953906311 hasAuthorship W2953906311A5002367971 @default.
• W2953906311 hasAuthorship W2953906311A5012816116 @default.
• W2953906311 hasAuthorship W2953906311A5012996195 @default.
• W2953906311 hasAuthorship W2953906311A5014752554 @default.
• W2953906311 hasAuthorship W2953906311A5030692760 @default.
• W2953906311 hasAuthorship W2953906311A5038576080 @default.
• W2953906311 hasAuthorship W2953906311A5043897574 @default.
• W2953906311 hasAuthorship W2953906311A5058605651 @default.
• W2953906311 hasAuthorship W2953906311A5061093150 @default.
• W2953906311 hasAuthorship W2953906311A5065043368 @default.
• W2953906311 hasAuthorship W2953906311A5070232710 @default.
• W2953906311 hasAuthorship W2953906311A5072476751 @default.
• W2953906311 hasAuthorship W2953906311A5076660780 @default.
• W2953906311 hasConcept C114614502 @default.
• W2953906311 hasConcept C126322002 @default.
• W2953906311 hasConcept C142724271 @default.
• W2953906311 hasConcept C143998085 @default.
• W2953906311 hasConcept C161921814 @default.
• W2953906311 hasConcept C197934379 @default.
• W2953906311 hasConcept C204787440 @default.
• W2953906311 hasConcept C27081682 @default.
• W2953906311 hasConcept C2778045022 @default.
• W2953906311 hasConcept C2778375690 @default.
• W2953906311 hasConcept C2778558090 @default.
• W2953906311 hasConcept C2779134260 @default.
• W2953906311 hasConcept C33923547 @default.
• W2953906311 hasConcept C71924100 @default.
• W2953906311 hasConcept C98274493 @default.
• W2953906311 hasConceptScore W2953906311C114614502 @default.
• W2953906311 hasConceptScore W2953906311C126322002 @default.
• W2953906311 hasConceptScore W2953906311C142724271 @default.
• W2953906311 hasConceptScore W2953906311C143998085 @default.
• W2953906311 hasConceptScore W2953906311C161921814 @default.
• W2953906311 hasConceptScore W2953906311C197934379 @default.
• W2953906311 hasConceptScore W2953906311C204787440 @default.
• W2953906311 hasConceptScore W2953906311C27081682 @default.
• W2953906311 hasConceptScore W2953906311C2778045022 @default.
• W2953906311 hasConceptScore W2953906311C2778375690 @default.
• W2953906311 hasConceptScore W2953906311C2778558090 @default.
• W2953906311 hasConceptScore W2953906311C2779134260 @default.
• W2953906311 hasConceptScore W2953906311C33923547 @default.
• W2953906311 hasConceptScore W2953906311C71924100 @default.
• W2953906311 hasConceptScore W2953906311C98274493 @default.
• W2953906311 hasOpenAccess W2953906311 @default.
• W2953906311 hasRelatedWork W2779339208 @default.
• W2953906311 hasRelatedWork W2802602953 @default.
• W2953906311 hasRelatedWork W2806618339 @default.
• W2953906311 hasRelatedWork W2808420309 @default.
• W2953906311 hasRelatedWork W2887168480 @default.
• W2953906311 hasRelatedWork W2986571496 @default.
• W2953906311 hasRelatedWork W2989973956 @default.
• W2953906311 hasRelatedWork W3035084006 @default.
• W2953906311 hasRelatedWork W3094135316 @default.
• W2953906311 hasRelatedWork W3114248459 @default.
• W2953906311 hasRelatedWork W3156936539 @default.
• W2953906311 hasRelatedWork W3157254743 @default.
• W2953906311 hasRelatedWork W3164733548 @default.
• W2953906311 hasRelatedWork W3184811931 @default.
• W2953906311 hasRelatedWork W3185891165 @default.
• W2953906311 hasRelatedWork W3185915088 @default.
• W2953906311 hasRelatedWork W3193837412 @default.
• W2953906311 hasRelatedWork W3198099375 @default.
• W2953906311 hasRelatedWork W3200253992 @default.
• W2953906311 hasRelatedWork W3214525382 @default.
• W2953906311 hasVolume "92" @default.
• W2953906311 isParatext "false" @default.
• W2953906311 isRetracted "false" @default.
• W2953906311 magId "2953906311" @default.
• W2953906311 workType "article" @default.